[Application and Research Progress of Lung Cancer Organoid in Precision Medicine 
for Lung Cancer]

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Precision medicine for lung cancer relies on molecular detection but faces challenges from tumor heterogeneity, impacting metastasis, recurrence, and drug resistance.
• Individual responses to lung cancer therapies vary even with identical genetic mutations, highlighting the need for personalized treatment strategies.

Purpose of the Study:

• To review the application progress and challenges of lung cancer organoids (LCOs) in advancing precision medicine for lung cancer.
• To highlight LCOs as a personalized tumor model that simulates in vivo tumor characteristics for improved lung cancer treatment strategies.

Main Methods:

• Review of current research on lung cancer organoid (LCO) technology.
• Discussion of co-culture models integrating LCOs with tumor microenvironments.
• Exploration of tissue engineering advancements, including microfluidic chips, for LCO applications.

Main Results:

• Lung cancer organoids (LCOs) effectively simulate in vivo tumor biology, supporting the use of novel therapeutics like antibody-drug conjugates.
• Advanced LCO models, including co-cultures and microfluidic systems, better preserve tumor tissue characteristics and enhance drug sensitivity screening.
• LCOs facilitate high-throughput and automated drug sensitivity experiments crucial for personalized lung cancer therapy.

Conclusions:

• Lung cancer organoids (LCOs) are vital tools for developing personalized treatment strategies in precision medicine for lung cancer.
• Continued development of LCO technology, particularly in co-culture and microfluidic applications, promises to further refine drug efficacy testing and patient outcomes.